---
schema_version: "secwatch.filing_event.v1"
accession: "0001792044-24-000031"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:49.922931+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt

## Summary
- Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.
- GAAP net earnings $95M ($0.08 diluted EPS); adjusted EBITDA ~$1.3B (+4% divestiture-adjusted); adjusted EPS $0.75 (+6%).
- Repaid ~$1.9B debt including make-whole call; expects to reach ~3.0x gross leverage target by year-end.
- Entered exclusive licensing agreement with Lexicon for sotagliflozin outside U.S. and Europe.
- Reaffirms 2024 full-year outlook: ~2% revenue growth on divestiture-adjusted operational basis.

## SEC filing metadata
- accession: 0001792044-24-000031
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000179204424000031/0001792044-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000179204424000031/vtrs-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001792044-24-000031
- JSON: https://secwatch.observer/filing/0001792044-24-000031.json
- Plain text: https://secwatch.observer/filing/0001792044-24-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.